Kathy Yi

Chief Financial Officer

Ms. Yi joined Cerevel Therapeutics in 2019 as chief financial officer. In this role, she will manage all aspects of Cerevel Therapeutics’ finances, help shape the strategic direction of the company to achieve key operational objectives, and guide effective resource allocation to drive the future growth of its portfolio.

Previously, Ms. Yi served as executive vice president, chief financial officer and secretary of Sangamo Therapeutics where she was responsible for leading the corporate finance, accounting, information technology, and facility operations functions. During her tenure, the company increased its market capitalization from about $300 million to over $1 billion, and more than doubled its headcount from nearly 120 employees to approximately 300 employees. She also oversaw and helped complete the closing of two research and development collaborations with Pfizer and Gilead totaling an upfront value of $220 million with potential for both near- and longer-term milestone and royalty payments.

Prior experience includes positions of increasing responsibility at Novartis, Life Technologies Corp., and Intel Corp. She began her career as a process/project engineer at Bechtel Corp., a leading global engineering, construction, and project management company. Ms. Yi earned her B.S. in Chemical Engineering from the University of California at Berkeley and an M.B.A. from Columbia Business School.